At the time of writing, Avidity Biosciences Inc [RNA] stock is trading at $47.23, up 1.40%. An important factor to consider is whether the stock is rising or falling in short-term value. The RNA shares have gain 4.33% over the last week, with a monthly amount glided 31.49%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Bernstein started tracking the stock with Outperform rating on June 24, 2025, and set its price target to $50. On June 17, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $55 on the stock. Raymond James started tracking the stock assigning a Strong Buy rating and suggested a price target of $65 on June 11, 2025. Citigroup initiated its recommendation with a Buy and recommended $70 as its price target on March 13, 2025. BMO Capital Markets started tracking with a Outperform rating for this stock on March 12, 2025, and assigned it a price target of $72. In a note dated March 07, 2025, Scotiabank initiated a Sector Outperform rating and provided a target price of $70 on this stock.
For the past year, the stock price of Avidity Biosciences Inc fluctuated between $21.51 and $56.00. Currently, Wall Street analysts expect the stock to reach $70 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $47.23 at the most recent close of the market. An investor can expect a potential return of 48.21% based on the average RNA price forecast.
Analyzing the RNA fundamentals
According to Avidity Biosciences Inc [NASDAQ:RNA], the company’s sales were 10.73M for trailing twelve months, which represents an 88.12% jump. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -48.63%, Pretax Profit Margin comes in at -42.48%, and Net Profit Margin reading is -42.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.33 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.77 points at the first support level, and at 44.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.16, and for the 2nd resistance point, it is at 49.09.
Ratios To Look Out For
It is important to note that Avidity Biosciences Inc [NASDAQ:RNA] has a current ratio of 9.26. On the other hand, the Quick Ratio is 9.26, and the Cash Ratio is 1.81. Considering the valuation of this stock, the price to sales ratio is 566.29, the price to book ratio is 4.78.
Transactions by insiders
Recent insider trading involved Gallagher Kathleen P., Chief Program Officer, that happened on Sep 02 ’25 when 188.0 shares were sold. President and CEO, Boyce Sarah completed a deal on Aug 28 ’25 to sell 25000.0 shares. Meanwhile, Director SARAH BOYCE bought 25000.0 shares on Aug 28 ’25.
